The relation between urinary angiotensinogen and proteinuria in renal AA amyloidosis patients

References

• Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898–909.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore) 1991;70:246–256.
   PubMed Web of Science ®Google Scholar
• Gertz MA. Secondary amyloidosis (AA). J Intern Med 1992;232:517–518.
   PubMedGoogle Scholar
• Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, de Jong PE, et al.; AIPRD Study Group. Angiotensin-Converting Enzymne Inhibition and Progression of Renal Disease. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001;60:1131–1140.
   PubMed Web of Science ®Google Scholar
• Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754–762.
   PubMed Web of Science ®Google Scholar
• Praga M, Hernández E, Montoyo C, Andrés A, Ruilope LM, Rodicio JL. Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 1992;20:240–248.
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456–1462.
   PubMed Web of Science ®Google Scholar
• Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73–87.
   PubMed Web of Science ®Google Scholar
• Dilek K, Usta M, Ersoy A, Ozdemir B, Yavuz M, Güllülü M, Yurtkuran M. Long-term effects of losartan on proteinuria and renal function in patients with renal amyloidosis. Scand J Urol Nephrol 2002;36:443–446.
   PubMed Web of Science ®Google Scholar
• Odabas AR, Cetinkaya R, Selcuk Y, Bilen H. Effect of losartan treatment on the proteinuria in normotensive patients having proteinuria due to secondary amyloidosis. Ups J Med Sci 2001;106:183–188.
   PubMed Web of Science ®Google Scholar
• Velez JC. The importance of the intrarenal renin-angiotensin system. Nat Clin Pract Nephrol 2009;5:89–100.
   Google Scholar
• Ketteler M, Noble NA, Border WA: Transforming growth factor-I3 and angiotensin II: the missing link from glomerular hyperfiltration to glomerulosclerosis? Ann Rev Physiol 1995;57:279–295.
   PubMed Web of Science ®Google Scholar
• Ruiz-Ortega M, Egido J. Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int 1997;52:1497–1510.
   PubMed Web of Science ®Google Scholar
• Kobori H, Nishiyama A, Harrison-Bernard LM, Navar LG. Urinary angiotensinogen as an indicator of intrarenal Angiotensin status in hypertension. Hypertension 2003;41:42–49.
   PubMed Web of Science ®Google Scholar
• Kobori H, Alper AB Jr, Shenava R, Katsurada A, Saito T, Ohashi N, Urushihara M, et al. Urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin system status in hypertensive patients. Hypertension 2009;53:344–350.
   PubMed Web of Science ®Google Scholar
• Urushihara M, Kondo S, Kagami S, Kobori H. Urinary angiotensinogen accurately reflects intrarenal Renin-Angiotensin system activity. Am J Nephrol 2010;31:318–325.
   PubMed Web of Science ®Google Scholar
• Saito T, Urushihara M, Kotani Y, Kagami S, Kobori H. Increased urinary angiotensinogen is precedent to increased urinary albumin in patients with type 1 diabetes. Am J Med Sci 2009;338:478–480.
   PubMed Web of Science ®Google Scholar
• Nishiyama A, Konishi Y, Ohashi N, Morikawa T, Urushihara M, Maeda I, Hamada M, et al. Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy. Nephrol Dial Transplant 2011;26:170–177.
   PubMed Web of Science ®Google Scholar
• Cohen EP, Kobori H, Moulder JE, Fish BL, Navar LG. Intrarenal angiotensinogen in radiation nephropathy (abstract) J Invest Med 2005;53:S288.
   Google Scholar
• Rohrwasser A, Morgan T, Dillon HF, Zhao L, Callaway CW, Hillas E, Zhang S, et al. Elements of a paracrine tubular renin-angiotensin system along the entire nephron. Hypertension 1999;34:1265–1274.
   PubMed Web of Science ®Google Scholar
• Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007;59:251–287.
   PubMed Web of Science ®Google Scholar
• Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension 2002;39:129–134.
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–470.
   PubMed Web of Science ®Google Scholar
• Ruiz-Ortega M, González S, Serón D, Condom E, Bustos C, Largo R, González E, et al. ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. Kidney Int 1995;48:1778–1791.
   PubMed Web of Science ®Google Scholar
• Obici L, Perfetti V, Palladini G, Moratti R, Merlini G. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005;1753:11–22.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24–29.
   PubMed Web of Science ®Google Scholar
• Berglund K, Thysell H, Keller C. Results, principles and pitfalls in the management of renal AA-amyloidosis; a 10-21 year followup of 16 patients with rheumatic disease treated with alkylating cytostatics. J Rheumatol 1993;20:2051–2057.
   PubMed Web of Science ®Google Scholar
• Ozen S. Renal amyloidosis in familial Mediterranean fever. Kidney Int 2004;65:1118–1127.
   Google Scholar
• Gottenberg JE, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B, Combe B, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum 2003;48:2019–2024.
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361–2371.
   PubMed Web of Science ®Google Scholar
• Mifsud SA, Allen TJ, Bertram JF, Hulthen UL, Kelly DJ, Cooper ME, Wilkinson-Berka JL, Gilbert RE. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia 2001;44:878–882.
   PubMed Web of Science ®Google Scholar
• Weir MR. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Clin Ther 2007;29:1803–1824.
   PubMed Web of Science ®Google Scholar
• Li J, Zhou C, Yu L, Wang H. Renal protective effects of blocking the intrarenal renin-angiotensin system. Hypertens Res 1999;22:223–228.
   Google Scholar
• Lee EY, Shim MS, Kim MJ, Hong SY, Shin YG, Chung CH. Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes. Exp Mol Med 2004;36:65–70.
   PubMedGoogle Scholar
• Vieitez P, Gómez O, Uceda ER, Vera ME, Molina-Holgado E. Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy. J Renin Angiotensin Aldosterone Syst 2008;9:96–102.
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Remuzzi G. Angiotensin-converting enzyme inhibitor therapy for non-diabetic progressive renal disease. Curr Opin Nephrol Hypertens 1997;6:489–495.
   PubMed Web of Science ®Google Scholar
• el Nahas AM. Renal scarring: the role of angiotensin II. Nephrol Dial Transplant 1995;10 Suppl 9:28–32.
   PubMed Web of Science ®Google Scholar
• Aybal Kutlugun A, Altun B, Buyukasik Y, Aki T, Turkmen E, Altindal M, Yildirim T, et al. Elevated urinary angiotensinogen a marker of intrarenal renin angiotensin system in hypertensive renal transplant recipients: does it play a role in development of proteinuria in hypertensive renal transplant patients? Transpl Int 2012;25:13–18.
   PubMedGoogle Scholar
• Kobori H, Ohashi N, Katsurada A, Miyata K, Satou R, Saito T, Yamamoto T. Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases. J Am Soc Hypertens 2008;2:349–354.
   PubMed Web of Science ®Google Scholar